News - Page 27 - Psychedelic Alpha

Read more about the article Psychedelic Bulletin #145: MAPS’ Second Phase 3 Study Published; EMA’s New Draft Guideline on Depression Drug Dev Includes Psychedelics; California’s Decrim. Bill Goes to Governor

Psychedelic Bulletin #145: MAPS’ Second Phase 3 Study Published; EMA’s New Draft Guideline on Depression Drug Dev Includes Psychedelics; California’s Decrim. Bill Goes to Governor

Post published:September 19, 2023
Post category:Psychedelic Bulletin

Read more about the article Numinus Takes Actions to Accelerate its Path to Profitability by Focusing on Positive Cash Flow Generating Operations

Numinus Takes Actions to Accelerate its Path to Profitability by Focusing on Positive Cash Flow Generating Operations

Post published:September 19, 2023
Post category:Press Release

Read more about the article COMPASS Pathways appoints Daphne Karydas to its Board of Directors

COMPASS Pathways appoints Daphne Karydas to its Board of Directors

Post published:September 19, 2023
Post category:Press Release

Read more about the article Clearmind Medicine Closes US$2.25 Million Public Offering

Clearmind Medicine Closes US$2.25 Million Public Offering

Post published:September 18, 2023
Post category:Press Release

Read more about the article Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression

Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression

Post published:September 18, 2023
Post category:Press Release

Read more about the article Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial

Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial

Post published:September 14, 2023
Post category:Press Release

Read more about the article Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering

Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering

Post published:September 14, 2023
Post category:Press Release

Read more about the article Second Phase 3 Study of MDMA-assisted Therapy Reports Positive Results, Paving Way for New Drug Application

Second Phase 3 Study of MDMA-assisted Therapy Reports Positive Results, Paving Way for New Drug Application

Post published:September 14, 2023
Post category:News

Read more about the article BetterLife Pharma to Host Investors Update Call on September 18, 2023

BetterLife Pharma to Host Investors Update Call on September 18, 2023

Post published:September 14, 2023
Post category:Press Release

Read more about the article atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Post published:September 14, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.